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The inclusion of antithymocyte globulin (ATG) in cord blood transplantation is controversial. We evaluated
outcomes according to ATG inclusion in 297 children and adolescents with acute lymphoblastic leukemia
(ALL) who received myeloablative total body irradiationebased conditioning and either single-unit (74%) or
double-unit (26%) grafts. Ninety-two patients (31%) received ATG and 205 (69%) did not. ATG recipients were
more likely to be cytomegalovirus seronegative. The incidences of day 100 grades II to IV acute graft-versus-
host disease (GVHD; 30% versus 54%, P ¼ .0002) and chronic GVHD (22% versus 43%, P ¼ .0008) were lower
with ATG compared with non-ATG regimens. However, day 100 grades III to IV acute GVHD was comparable
(11% versus 17%, P ¼ .15). The 3-year incidences of transplant-related mortality (16% versus 17%, P ¼ .98),
relapse (17% versus 27%, P ¼ .12), and leukemia-free survival (66% versus 55%, P ¼ .23) in ATG and non-ATG
recipients were similar. There were no differences in viral reactivation between treatment groups (60% versus
58%, P ¼ .83). Therefore, the data suggest that incorporation of ATG with myeloablative conditioning regimens
may be useful in reducing the risk of acute and chronic GVHD without any deleterious effect on transplant-
related mortality, relapse, or leukemia-free survival in children and adolescents with ALL.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common
indication for allogeneic transplantation in children and
adolescents. In the absence of an HLA-matched sibling or
adult unrelated donor, cord blood is frequently used as an
alternative source of hematopoietic stem cells for allogeneicdgments on page 2178.
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ty for Blood and Marrow Transplantation.transplantation. In cord blood transplantation (CBT) for
pediatric ALL, however, the addition of antithymocyte glob-
ulin (ATG) to transplant conditioning is controversial. ATG is
a potent immunosuppressive agent that induces T cell
clearance from the circulation and suppresses T cell activa-
tion, homing, and cytotoxic activities [1]. ATGmay also cause
induction of apoptosis in B cell lineages [2] and interference
with dendritic cell function [2-4]. Formulations of ATG that
are generated by immunization of horse or rabbit with
human thymocytes also have direct effects on the thymus,
impairing thymic output, particularly of CD4þ T cells
including regulatory T cells [5]. The resultant in vivo T cell
depletion has been used to prevent graft rejection and
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known to cause profound T cell deﬁciency and repertoire
restriction after allogeneic transplantation [6], which may
also increase the risk of mortality because of serious oppor-
tunistic infections and leukemia recurrence [5,7-10].
In myeloablative adult unrelated donor transplantation
for hematologic malignancy, ATG has been associated with a
lower incidence and severity of chronic GVHD and reduced
late mortality risk [11,12]. In contrast, in reduced-intensity or
nonmyeloablative conditioning for hematologic malignancy,
a higher relapse risk and lower leukemia-free survival have
been observed with the use of ATG [10]. In myeloablative
unrelated adult donor transplantation for ALL in children and
adolescents, Veys et al. [13], using data reported to the Center
for International Blood and Marrow Transplant Research
(CIBMTR), demonstrated comparable transplant-related
mortality, relapse, and leukemia-free survival regardless of
whether ATG or alemtuzumab were included in trans-
plantation regimens. In that report, all transplant condi-
tioning regimens included total body irradiation (TBI) doses
of 1000 cGy or higher.
Reports in children and adolescents undergoing CBT
support the concept that inclusion of ATG to conditioning
regimens is not optimal with respect to immune reconstitu-
tion or survival [14,15]. Lindemans et al. [14] reported the
results of ATG inclusion in recipients of myeloablative or
nonmyeloablative conditioning for malignant and nonma-
lignant diseases and found that although the probability of
severe acute GVHD was lower in the ATG-containing group,
immune reconstitution was delayed and viral reactivations
was higher in this group. However, survival was similar
among recipients of ATG-containing and non-ATGecontain-
ing regimens. Pascal et al. [15] from the Eurocord reported
lower GVHD, higher transplant-related mortality, and lower
survival with ATG-containing (rabbit derived) compared
with non-ATGecontaining regimens after myeloablative CBT
for acute leukemia, myelodysplastic/myeloproliferative syn-
dromes, and lymphoma.
Because ATG is routinely used, in the current analysis we
sought to investigate the risks and beneﬁts of including ATG
to a myeloablative TBI-containing conditioning regimen for
ALL in a recent cohort of children and adolescents who
received CBT reported to the CIBMTR. Our hypothesis was
that inclusion of ATG would lead to lower leukemia-free
survival.METHODS
Data Source
The CIBMTR is a voluntary working group of transplant centers world-
wide that contribute consecutive data on allogeneic and autologous trans-
plants performed at their centers. Patients are followed longitudinally. Legal
guardians and/or patients provided informed consent for research. The
institutional review boards of the Medical College of Wisconsin and the
National Marrow Donor Program approved this study.Eligibility Criteria
Patients had a diagnosis of ALL, were younger than 21 years, were in
complete remission (CR) at transplantation, received a myeloablative TBI
conditioning regimen (TBI dose 1000 cGy) with chemotherapeutic agents,
and were transplanted in the United States. Single-unit grafts had a total
nucleated cell (TNC) dose  2.5  107/kg patient body weight before cryo-
preservation, whereas in double-unit grafts each unit had a TNC 1.5 107/
kg and therefore a total cryopreserved TNC  3  107/kg. Patients were
excluded if they were in morphologic relapse, had refractory disease, or
received reduced-intensity conditioning regimens.Endpoints
Time to neutrophil recovery was deﬁned as the ﬁrst of 3 consecutive
days with a sustained absolute neutrophil count  .5  109/L and time to
platelet recovery, the ﬁrst of 3 consecutive days 20  109/L, and 7 days
without platelet transfusion support. Grading of acute GVHD and diagnosis
of chronic GVHD were based on standard criteria [16,17]. Relapse was
deﬁned as morphologic or cytogenetic recurrence. Death in CR was
considered as transplant-related mortality. Treatment failure was deﬁned as
relapse or death from any cause (inverse of leukemia-free survival).
Surviving patients were censored at last follow-up.
Statistical Analysis
Patient-, disease-, and transplant-related factors were compared be-
tween transplantations that included ATG in the conditioning regimen and
non-ATG regimens with the chi-square test for categorical variables and the
Wilcoxon 2-sample test for continuous variables. The probabilities of
leukemia-free and overall survival were calculated using the Kaplan-Meier
estimator [18]. The probabilities of hematopoietic recovery, acute and
chronic GVHD, transplant-related mortality, and relapse were calculated
using the cumulative incidence estimator [19].
Cox regression models were built to study the effect of ATG-containing
compared with non-ATGecontaining regimens for GVHD, transplant-
related mortality, relapse, treatment failure, and overall mortality. Logistic
regression models were built for neutrophil and platelet recovery. The
following variables were tested: the inclusion of ATG versus none to con-
ditioning regimens, age (5 versus 6 to 10 versus 11 to 20 years), sex (male
versus female), performance score (90, 100 versus <90), race (white versus
nonwhite), disease status (ﬁrst CR versus second CR/third CR), recipient
cytomegalovirus serostatus (positive versus negative), TNC dose (<3.0
versus 3.0 - 5.0 versus 5.0  107/kg), GVHD prophylaxis (calcineurin
inhibitor [CNI] þ mycophenolate versus CNI þ methotrexate versus CNI
alone), and transplant period (2007 to 2008 versus 2009 to 2011). A step-
wise model selection approach was used to identify all signiﬁcant risk fac-
tors. Variables that attained a signiﬁcance level of .05 or less were held in the
ﬁnal model. The chronic GVHD model was stratiﬁed by HLA match and
transplant-related mortality model by TNC due to nonproportionality. There
were no signiﬁcant interactions between variables held in the ﬁnal model
and the inclusion of ATG versus none in transplant conditioning regimens.
All P values are 2-sided, and analyses were performed using SAS version 9.3
(SAS Institute, Cary, NC).
RESULTS
Patient and Transplant Characteristics
Table 1 summarizes patient, disease, and transplant
characteristics. Transplants were performed between 2007
and 2011 in the United States at 71 centers. Transplant con-
ditioning regimens at 14 centers included ATG-containing
and non-ATGecontaining regimens, at 17 centers used only
ATG-containing regimens, and at 40 centers included non-
ATGecontaining regimens. Patients had similar distributions
of gender and race, but ATG recipients were younger and less
likely to have performance scores of 90 to 100 or to be
cytomegalovirus seropositive. Disease status was similar in
the 2 groups, with approximately two thirds of all patients
transplanted in second or third CR.
ATG recipients were more likely to receive a single-cord
blood unit. Approximately 60% of recipients of single-unit
and double-unit CBT received TNC dose > 5  107/kg.
Donorerecipient HLA match was similar across the 2 treat-
ment groups. Cord blood units were 4-6/6 HLA-matched to
the recipient at HLA-A and -B (antigen level) and HLA-DRB1
(allele level). For double-unit grafts the transplantation was
assigned the worst HLA match between the recipient and
cord blood unit (eg, if 1 unit was 6/6 HLA-matched and the
other unit 4/6 HLA-matched to the recipient, the trans-
plantation was assigned 4/6 HLA-matched).
The most common ATG source was horse derived (n¼ 58,
63%); the remaining patients received rabbit derived ATG
(n ¼ 33; 37%). In non-ATG recipients CNI with mycopheno-
late was the predominant GVHD prophylaxis regimen. In the
ATG group CNI alone was most likely to be used. The median
follow-up of both groups was 3 years.
Table 1
Patient, Disease, and Transplant Characteristics
ATG-Containing Non ATGeContaining P
TBI þ Cyclophosphamide* TBI þ Cyclophosphamidey
Number of patients 92 205
Age at transplant .20
5 yr 29 (32) 52 (25)
6-10 yr 36 (39) 71 (35)
11-20 yr 27 (29) 82 (40)
Gender .15
Male 52 (57) 134 (65)
Performance score .003
<90% 13 (14) 26 (13)
90% 69 (75) 175 (85)
Not reported 10 (11) 4 (2)
Race .30
White 77 (84) 161 (79)
Nonwhite 15 (16) 44 (21)
Recipient cytomegalovirus serostatus .02
Positive 39 (42) 114 (56)
Negative 51 (55) 91 (44)
Not reported 2 (2) __
Disease status .57
First CR 35 (38) 71 (35)
Second/third CR 57 (62) 134 (65)
GVHD prophylaxis <.001
Tacrolimus/cyclosporine þ mycophenolate 28 (30) 143 (70)
Tacrolimus/cyclosporine þ methotrexate 12 (13) 48 (23)
Tacrolimus/cyclosporine alone 52 (57) 14 (7)
Number of cord blood units infused <.001
One 82 (89) 138 (67)
Two 10 (11) 67 (33)
Median infused TNC dose, 107/kg (range) 5 (2-31) 5 (2-20) .90
TNC dose, 107/kg .53
<3 13 (14) 21 (10)
3-5 25 (27) 65 (32)
5 54 (59) 119 (58)
Donorerecipient HLA match .38
4/6 30 (33) 72 (35)
5/6 42 (46) 102 (50)
6/6 20 (22) 31 (15)
Transplant period .75
2007-2008 35 (38) 82 (40)
2009-2011 57 (62) 123 (60)
Values in parentheses are percents, unless otherwise indicated.
* TBIþ cyclophosphamideþ ATG: TBIþ cyclophosphamideþ ﬂudarabine (n¼ 6), TBIþ cyclophosphamide only (n¼ 49), TBIþ cyclophosphamideþ thiotepa
(n¼ 19), TBIþ cyclophosphamideþ etoposide (n¼ 15), TBIþ cyclophosphamide þ cytosine arabinoside (n¼ 2), TBIþ cyclophosphamide þ clofarabine (n¼ 1).
y TBI þ cyclophosphamide (non-ATG) cohort: TBI þ cyclophosphamide þ ﬂudarabine (n ¼ 135), TBI þ cyclophosphamide only (n ¼ 11), TBI þ
cyclophosphamide þ thiotepa (n ¼ 42), TBI þ cyclophosphamide þ etoposide (n ¼ 9), TBI þ cyclophosphamide þ cytosine arabinoside (n ¼ 8).
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Themedian time to neutrophil recoverywas not different,
21 days (range, 10 to 58) in ATG recipients and 22 days
(range, 12 to 77) in non-ATG recipients. There was no dif-
ference in the incidence of neutrophil recovery at day 28, 72%
(95% conﬁdence interval [CI], 62% to 80%) in ATG recipients
versus 67% (95% CI, 61% to 74%) in non-ATG recipients
(P¼ .15). Additionally, the incidence of neutrophil recovery at
day 45 was also similar between the 2 groups, 93% (95% CI,
88% to 98%) and 90% (95% CI, 86% to 94%) in ATG and non-
ATG recipients, respectively (P ¼ .15). However, in multivar-
iate analysis the likelihood of recovery at day 28 was higher
with ATG-containing compared with non-ATGecontaining
regimens (odds ratio [OR], 1.82; 95% CI, .99 to 3.34; P ¼ .05),
but the observed effect was only marginally signiﬁcant for
the threshold set for this analysis. None of the other factors
tested for, including disease status at transplantation, HLA
match, and TNC, was associated with neutrophil recovery.
Secondary graft failure was low and occurred in 1 ATG
recipient and 4 non-ATG recipients (P ¼ .59).
There were no differences in median time to platelet
recovery by inclusion of ATG to conditioning regimens:49 days (range, 14 to 127) and 48 days (range, 23 to 433) for
ATG-containing and non-ATGecontaining regimens,
respectively. The day 100 incidence of platelet recovery was
higher for ATG-containing regimens at 84% (95% CI, 76% to
91%) compared with 73% (95% CI, 66% to 79%) for non-
ATGecontaining regimens (P¼ .004). In multivariate analysis
the likelihood of platelet recovery at day 100was higher with
ATG-containing compared with non-ATGecontaining regi-
mens (OR, 4.36; 95% CI, 1.55 to 12.24; P ¼ .005). Additionally,
platelet recovery was lower in patients aged 11 to 20 years
compared with younger recipients (OR, .17; 95% CI, .05 to .53;
P ¼ .002) and in those transplanted in second or third CR
comparedwith those transplanted in ﬁrst CR (OR, .38; 95% CI,
.16 to .89; P ¼ .03).
Acute and Chronic GVHD
Recipients of ATG-containing regimens had signiﬁcantly
lower day 100 incidence of grades II to IV acute GVHD of 30%
(95% CI, 21% to 40%) compared with recipients of non-
ATGecontaining regimens at 54% (95%CI, 47% to 61%;P< .001;
Figure 1A). Among recipients of non-ATGecontaining regi-
mens, theday 100 incidenceof grades II to IV acuteGVHDafter
Figure 1. (A) Cumulative incidence of grades II to IV acute GVHD. (B) Cumulative incidence of grades III to IV acute GVHD.
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compared with 58% (95% CI, 46% to 70%) after transplantation
of 2 units. However, the day 100 incidence of grades III to IV
acuteGVHDwasnotdifferent between the2 treatmentgroups
(11% [95%CI, 5% to 18%] of 1 unit and17% [95%CI,12% to 23%] of
2 units; P ¼ .15; Figure 1B).
In multivariate analysis, ATG-containing regimens were
associated with signiﬁcantly lower risks of grades II to IV
acute GVHD compared with non-ATGecontaining regimens
(Table 2). There were no differences in grades II to IV acute
GVHD risks by ATG type (rabbit versus horse: hazard ratio
[HR], .99; 95% CI, .47 to 2.09; P ¼ .9). Grades II to IV acute
GVHD was lower in patients aged 11 to 20 years compared
with those younger than 5 years (HR, .57; 95% CI, .37 to .88;
P ¼ .01) and those aged 5 to 10 years (HR, .56; 95% CI, .38 to
.84; P ¼ .005). The effect of age on acute GVHD risk was in-
dependent of inclusion of ATG to conditioning regimens.
Results of multivariate analysis conﬁrmed grades III to IV
acute GVHD risks were not different between treatment
groups (Table 2). Among patients with grades III to IV acute
GVHD, gut involvement was more common with non-
ATGecontaining regimens (P ¼ .04).
The 3-year cumulative incidence of chronic GVHD in re-
cipients of ATG-containing conditioning regimens was lower
at 22% (95% CI, 14% to 31%) compared with 43% (95% CI, 36%Table 2
Risks Associated with Inclusion of ATG in Transplant Conditioning Regimens
Compared with Non-ATGeContaining Regimens
Outcome HR (95% CI) P
Acute grades II-IV GVHD
Non-ATGecontaining 1.00
ATG-containing .44 (.29-.65) <.0001
Acute grades III-IV GVHD
Non-ATGecontaining 1.00
ATG-containing .60 (.30-1.22) .16
Chronic GVHD
Non-ATGecontaining 1.00
ATG-containing .43 (.26-.71) .0009
Relapse
Non-ATGecontaining 1.00
ATG-containing .85 (.41-1.75) .66
Transplant-related mortality
Non-ATGecontaining 1.00
ATG-containing 1.02 (.55-1.88) .97
Treatment failure
Non-ATGecontaining 1.00
ATG-containing 1.28 (.85-1.93) .24
Overall mortality
Non-ATGecontaining 1.00
ATG-containing .96 (.61-1.50) .85to 50%) in recipients of non-ATGecontaining regimens
(P < .001) (Figure 2). Among recipients of non-
ATGecontaining regimens, the 3-year incidence of chronic
GVHD after transplantation of 1 unit was 42% (95% CI, 34% to
51%) compared with 44% (95% CI, 32% to 56%) after trans-
plantation of 2 units. In multivariate analysis chronic GVHD
risks were lower with ATG-containing compared with non-
ATGecontaining conditioning regimens when stratiﬁed for
HLA matching (Table 2). However, among those reported to
have chronic GVHD, there were no differences in the severity
of GVHD (P ¼ .19). Ten of 19 patients (53%) who received
ATG-containing regimens reported mild chronic GVHD
compared with 56 of 81 patients (69%) who received non-
ATGeconditioning regimens. The corresponding rates for
moderate or severe chronic GVHD was 9 (47%) and 25 (31%).
The median duration of immunosuppression for chronic
GVHD treatment did not differ by treatment groups, 20
months for ATG recipients and 22 months for non-ATG
recipients. Additionally, there were no differences in
chronic GVHD risks by rabbit versus horse ATG (HR, .99; 95%
CI, .47 to 2.09; P ¼ .9).Transplant-Related Mortality and Relapse
The 3-year cumulative incidences of transplant-related
mortality were not different between treatment groups:
16% (95% CI, 10% to 25%) after ATG-containing regimens and
17% (95% CI, 13% to 23%) after non-ATGecontaining regimens
(P ¼ .98). In multivariate analysis, transplant-related mor-
tality risks were not different after ATG-containing and non-
ATGecontaining regimens (Table 2) stratiﬁed for TNC dose of
cord blood unit(s). However, risks were higher for patients
who were cytomegalovirus seropositive compared with
those who were seronegative (HR, 1.85; 95% CI, 1.03 to 3.32;
P ¼ .04).
Data on infections within the ﬁrst 100 days after trans-
plantation was available for 90 of 92 recipients of
ATG-containing and 202 of 205 recipients of non-
ATGecontaining regimens. We did not observe differences in
viral, bacterial, or fungal infections by treatment group. Fifty-
ﬁve of 92 recipients (60%) reported viral infections with ATG-
containing regimens compared with 118 of 205 recipients
(58%) of non-ATGecontaining regimens (P ¼ .83). The corre-
sponding rates for bacterial and fungal infections were 53 of
92 (58%) versus 125 of 205 (61%; P ¼ .88) and 9 of 92 (10%)
versus 19 of 205 (9%; P ¼ .90), respectively. Only 2 patients
were reported to have Epstein-Barr virus post-transplant
lymphoproliferative disease (1 in the ATG group and 1 in the
non-ATG group), and no deaths were directly attributed to
Figure 2. Cumulative incidence of chronic GVHD.
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disease.
The 3-year cumulative incidences of relapse were not
different in the 2 treatment groups: 17% (95% CI, 10% to 26%)
after ATG-containing regimens and 27% (95% CI, 21% to 34%;
P ¼ .12), after non-ATG containing regimens. In multivariate
analysis relapse risks after ATG-containing and non-
ATGecontaining regimens were not different (Table 2).
Relapse risks were higher for patients transplanted in second
or subsequent remission compared with ﬁrst remission (HR,
2.18; 95% CI, 1.22 to 3.89; P ¼ .008), and this effect was in-
dependent of whether ATG was included in the condition
regimen.
Overall Survival and Leukemia-Free Survival
There were no signiﬁcant differences in overall and
leukemia-free survival between the treatment groups. The 3-
year probability of overall survival after ATG-containing and
non-ATGecontaining regimens were 67% (95% CI, 57% to
77%) and 65% (95% CI, 58% to 72%), respectively (P ¼ .76). The
corresponding leukemia-free survival rates were 66% (95%
CI, 56% to 76%) and 55% (95% CI, 48% to 62%), respectively (P¼
.23; Figure 3). In multivariate analysis there were no signif-
icant differences in overall mortality or treatment failure
after ATG-containing compared with non-ATGecontaining
conditioning regimens (Table 2). Transplantation in second
or subsequent remission was associated with higher mor-
tality (HR, 2.01; 95% CI, 1.25 to 3.24; P ¼ .004) and treatment
failure (HR, 2.01; 95% CI, 1.31 to 3.08; P ¼ .001). Additionally,
patients who were cytomegalovirus seropositive were at
higher risk for mortality compared with those who were
seronegative (HR, 1.85; 95% CI, 1.22 to 2.86; P ¼ .004).Figure 3. Probability of leukemia-free survival.Causes of Death
The primary causes of death by treatment group are
shown in Table 3. A similar proportion of patients died in the
ATG group (29/92, 32%) when compared with the non-ATG
group (69/205, 34%; P ¼ .22). The most common cause of
death in both groups was leukemia recurrence, accounting
for about half of all deaths in each treatment group. Other
common causes of mortality in the ATG group were GVHD
and infection, accounting for a third of deaths. Other com-
mon causes of mortality in the non-ATG group included graft
failure, GVHD, and infection, accounting for 40% of deaths.
DISCUSSION
In this study we examined the inclusion of ATG to
transplant conditioning regimens for children and adoles-
cents with ALL undergoing CBT and receiving myeloablative
TBI-containing regimens. Our study demonstrated that the
inclusion of ATG to the transplant conditioning regimen
resulted in lower rates of grades II to IV acute GVHD and
chronic GVHD but not grades III to IV acute GVHD. Despite
lower GVHD risks, transplant-related mortality, relapse, and
leukemia-free and overall survival were not different be-
tween the treatment groups. We did not observe an effect of
GVHD prophylaxis regimens on acute or chronic GVHD risks.
These ﬁndings are consistent with the report of Veys et al.
[13] in a similar population of patients after unrelated adult
donor transplantation. In that report in vivo T cell depletion
had no effect on transplant-related mortality, relapse, sur-
vival, and leukemia-free survival despite lower acute and
chronic GVHD. However, our ﬁndings differ from the report
by Pascal et al. [15] where mortality was higher with rabbit-
derived ATG in the setting of myeloablative CBT for acute
leukemia, lymphoma, and myelodysplastic/myeloprolifera-
tive syndrome. The myeloablative TBI-containing regimen is
immunosuppressive and the only regimen in the current
analysis. In this setting it is plausible that the addition of ATG
may not have introduced marked differences in immune
reconstitution in recipients of ATG-containing and non-
ATGecontaining regimens.
Our ﬁndings have a number of important implications for
CBT. ATG was originally included in CBT conditioning regi-
mens to prevent graft rejection and GVHD. Both complica-
tions were initially a major concern given the low progenitor
cell dose and the high degree of HLAmismatch inherent in CB
grafts [20,21]. To date, however, the beneﬁt of ATG in relation
to neutrophil engraftment is unproven, with the exception of
nonmyeloablative regimens in the setting of CBT for re-
cipients who have not received prior therapy with immu-
nosuppressive properties [22]. The current analysis showed
an early margin advantage with ATG for neutrophil recovery
and a signiﬁcant advantage for platelet recovery. Inferior
platelet recoverywith non-ATGecontaining regimensmay in
part be explained by the higher rates of acute GVHD and the
effects of additional immune suppression for GVHDTable 3
Causes of Death
ATG (n ¼ 29) Non-ATG (n ¼ 69)
Relapse 13 (45%) 34 (49%)
Graft failure 2 (7%) 8 (12%)
GVHD 7 (24%) 6 (9%)
Infection 3 (10%) 13 (19%)
Organ failure 1 (3%) 4 (6%)
Idiopathic pneumonia syndrome 2 (7%) 4 (6%)
Hemorrhage 1 (7%) d
D.M. Ponce et al. / Biol Blood Marrow Transplant 21 (2015) 2173e21792178treatment. Low cell dose is no longer a concern because cell
doses in excess of 3  107/kg, the accepted minimum for
engraftment, were delivered with either a single cord blood
unit or by infusing 2 units. In fact, over half of transplants in
the current analysis received cell doses >5  107/kg.
From the standpoint of grades II to IV acute and chronic
GVHD, the fact that ATG-containing conditioning regimens
were associated with a lower incidence of acute GVHD and
chronic GVHD is consistent with adult donor allograft series
[10-13] and CBT series [8,14,23-26]. Moreover, partial abro-
gation of GVHD risk was not associated with a demonstrable
reduction in transplant-related mortality or higher leukemia
relapse. However, chronic GVHD is debilitating, and others
have reported on the deleterious effects of chronic GVHD on
health-related quality of life [27]. Data on immune recon-
stitution were not available in this analysis, unlike other CBT
series [5,7,9,26,28]. In vivo T cell depletion may induce
slower immune reconstitution that may offset any beneﬁt of
GVHD reduction. However, we did not observe differences in
rates of viral reactivation or bacterial and fungal infections
between the treatment groups. If viral reactivation were to
be used as a surrogate for early immune reconstitution, the
current analysis suggests no signiﬁcant differences between
ATG-containing and non-ATGecontaining regimens. The
current analysis used data reported to an observational
registry, and it is challenging to collect data on immune
reconstitution systematically and consistently in the setting
of practice variation between transplant centers.
Complicating the assessment of the risks and beneﬁts of
pretransplant ATG is the possibility that the impact of ATG
inclusion may vary according to the dose of ATG, the formu-
lation used, and the timing of administration in relation to the
infusion of the graft. A subset analysis by ATG type (rabbit
versus horse) in the current analysis failed to show signiﬁcant
differences in acute and chronic GVHD. In a study of 127
pediatric CBT recipients with malignant and nonmalignant
hematologic diseases, Lindemans et al. [14] reported that
those transplanted without ATG had more GVHD, better im-
mune reconstitution, and lower rates of viral reactivation
compared with those who received ATG immediately before
CB infusion, although survival was similar in both groups.
In another report, Admiraal et al. [28] evaluated ATG phar-
macokinetics in 280 pediatric allograft recipients with ma-
lignant and nonmalignant hematologic diseases. They found
that high post-transplantation ATG exposure was associated
with a lower incidence of grades II to IV acute GVHD, worse
T cell recovery, and lower survival. These ﬁndings suggest
that individualized ATG dosing guided by pharmacokinetic
analyses may optimize exposure and potentially clinical
outcomes. A limitation of the Lindeman and Admiraal reports
is the heterogeneity of the population with respect to dis-
eases studied, conditioning regimen intensity, and donor/
graft types. Therefore, it remains to be seen if their observa-
tions would hold true in a homogenous population with ALL
who received myeloablative TBI-containing conditioning
regimen.
Almost a decade ago Parkman et al. [29] reported lower
relapse risks in children with acute leukemia and successful
immune reconstitution after single-unit myeloablative CBT.
In that report, all patients received myeloablative condi-
tioning regimens, which is more comparable with the pop-
ulation in the current analysis. Because there were no
differences in relapse risks in patients who received ATG and
those who did not in the current analysis, it is plausible that
immune reconstitution in recipients of ATG-containing andnon-ATGecontaining regimens were not signiﬁcantly
different when a myeloablative dose of TBI was included in
the regimen.
The omission of ATG from myeloablative TBI-containing
regimens did not improve leukemia-free survival as hy-
pothesized. Conditioning regimen strategies, including use of
ATG and its dose and timing, are best studied in the setting of
randomized trials for speciﬁc populations (diseases and
conditioning regimens) with well-deﬁned clinical and labo-
ratory endpoints that include immune reconstitution. In the
absence of such trials, data from transplant registries may be
used to guide clinical care. Data from the current analysis
support the inclusion of ATG tomyeloablative TBI-containing
conditioning regimens for ALL in children and adolescents in
that it is associated with lower grades II to IV acute and
chronic GVHD compared with non-ATGecontaining regi-
mens. Leukemia relapse and survival are not compromised
with ATG inclusion, and lowering GVHD is likely to lower the
burden of morbidity in children.
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